Publicação
Recalcitrant Acneiform Eruption Revealing Behçet’s Disease: A Case with Late but Successful Response to Adalimumab
| Resumo: | Behçet's disease is a systemic vasculitis with a chronic-relapsing course, which can lead to significant morbidity and mortality. From the often-compelling challenge of making a prompt diagnosis comes the difficulty in its treatment. We report the case of a patient with an acneiform skin eruption revealing Behçet's disease that was refractory to conventional therapy and later completely responded to adalimumab. Although randomized controlled clinical trials are lacking in the literature, there is already significant evidence supporting anti-TNF agents as a major therapeutic advance in Behçet's disease, particularly in cases that are severe, refractory or intolerant to classical immunosuppression. |
|---|---|
| Autores principais: | Vide, Júlia |
| Outros Autores: | Lopes, Sofia; Magina, Sofia; Azevedo, Filomena |
| Assunto: | Acneiform Eruptions Adalimumab Tumor Necrosis Factor-alpha/antagonists & inhibitors Behcet Syndrome Adalimumab Erupções Acneiformes Factor de Necrose Tumoral alfa /antagonistas & inibidores Síndrome de Behçet |
| Ano: | 2018 |
| País: | Portugal |
| Tipo de documento: | artigo |
| Instituição associada: | Sociedade Portuguesa de Dermatologia e Venereologia |
| Idioma: | inglês |
| Origem: | Portuguese Journal of Dermatology |
| Resumo: | Behçet's disease is a systemic vasculitis with a chronic-relapsing course, which can lead to significant morbidity and mortality. From the often-compelling challenge of making a prompt diagnosis comes the difficulty in its treatment. We report the case of a patient with an acneiform skin eruption revealing Behçet's disease that was refractory to conventional therapy and later completely responded to adalimumab. Although randomized controlled clinical trials are lacking in the literature, there is already significant evidence supporting anti-TNF agents as a major therapeutic advance in Behçet's disease, particularly in cases that are severe, refractory or intolerant to classical immunosuppression. |
|---|